|
| | Aprepitant Impurity 6 Basic information |
| Product Name: | Aprepitant Impurity 6 | | Synonyms: | Aprepitant Impurity 6;Fosaprepitant Dimeglumine Impurity A;Aprepitant Impurity 5(S,R,S-Isomer);Aprepitant impurity 9/(1S,2R,3S)-Aprepitant;1S, 2R, 3S-Aripitan;Arepitam impurity isomers (1S, 2R, 3S);5-([(2R,3S)-2-((S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluoro phenyl)morpholino]methyl)-1H-1,2,4-triazol-3(2H)-one;3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- | | CAS: | 170902-81-5 | | MF: | C23H21F7N4O3 | | MW: | 534.43 | | EINECS: | | | Product Categories: | | | Mol File: | 170902-81-5.mol |  |
| | Aprepitant Impurity 6 Chemical Properties |
| density | 1.51±0.1 g/cm3(Predicted) | | pka | 8.06±0.20(Predicted) |
| | Aprepitant Impurity 6 Usage And Synthesis |
| Uses | [1(S)-Phenylethoxy]-Aprepitant is a derivative of Aprepitant (A729800), a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. |
| | Aprepitant Impurity 6 Preparation Products And Raw materials |
|
